Ravi Salgia to Azabicyclo Compounds
This is a "connection" page, showing publications Ravi Salgia has written about Azabicyclo Compounds.
Connection Strength
0.109
-
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65.
Score: 0.109
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.